/Companies

Yuva Bioscences

Birmingham, US · Founded 2019 · 6 known investors

Find your way into Yuva Bioscences

Sign up to see every warm intro you have to Yuva Bioscences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Yuva Bioscences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Yuva Biosciences develops and licenses Y100, a cosmetic active ingredient that enhances mitochondrial health to reduce visible signs of aging for use in skincare and haircare products.

Founders & leadership

GS
Greg SchmergelExecutive

Board

FE
Fred EhrsamBoard director
DB
Daniel BrowneBoard director

Investors · 6

Also in the syndicate · 2

Atma CapitalLongevity Tech Fund

Reported raises · per SEC filings

Form D private placements

$1.1M disclosed across 1 of 2 rounds · 2023–2026

▶$1.1MraisedMar 2026 · 11 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Greg SchmergelExecutive Officer, Director
  • Fred EhrsamDirector
  • Daniel BrowneDirector
Offering amount
$3M
Amount sold
$1.1M
First sale
Mar 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MofferedNov 2023 · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Greg SchmergelExecutive Officer, Director
Offering amount
$4.5M
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Ideaya BiosciencesIDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
VedaBioVedaBio develops a molecular detection platform using CRISPR technology that enables rapid, accurate detection of multiple biological targets without the need for amplification. The platform serves research, diagnostics, and industrial applications across multiple markets.
ImvivabioA clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases, targeting off-the-shelf and scalable treatments to improve patient access.
Huya Bioscience InternationalHUYABIO International develops novel biopharmaceutical products originating in China for global markets, working with biopharmaceutical, academic and commercial partners to advance drug candidates across all therapeutic areas. It maintains a large China-sourced compound portfolio and operates offices across the US, Japan, South Korea, Canada, Ireland and China.
Iovance BiotherapeuticsIovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.

Companies working in the same space as Yuva Bioscences.

Frequently asked questions

What does Yuva Bioscences do?
Yuva Biosciences develops and licenses Y100, a cosmetic active ingredient that enhances mitochondrial health to reduce visible signs of aging for use in skincare and haircare products.
Who are Yuva Bioscences's investors?
Yuva Bioscences's investors include Innovation Depot, TBD Angels, Western Technology Investment, VentureSouth.
How much funding has Yuva Bioscences raised?
Yuva Bioscences has disclosed $1.1M raised across 1 of its 2 known rounds.
Where is Yuva Bioscences headquartered?
Yuva Bioscences is headquartered in Birmingham, US.